Using a modified herpes virus to deliver cancer-fighting antibodies for brain tumors
An engineered oncolytic herpes virus expressing a full-length α-CD47 mAb for the treatment of GBM
['FUNDING_OTHER'] · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · NIH-10928767
This study is testing a new treatment for glioblastoma, a tough type of brain cancer, using a specially modified herpes virus that helps the immune system fight the cancer more effectively by targeting a protein that helps cancer cells hide.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE (nih funded) |
| Locations | 1 site (DUARTE, UNITED STATES) |
| Trial ID | NIH-10928767 on ClinicalTrials.gov |
What this research studies
This research investigates a novel treatment for glioblastoma, a severe type of brain cancer, by using an engineered herpes virus that can produce and release a specific antibody directly at the tumor site. The approach combines oncolytic virotherapy with monoclonal antibody immunotherapy, aiming to enhance the immune system's ability to attack cancer cells. By targeting the CD47 protein, which helps cancer cells evade the immune system, this therapy seeks to improve patient outcomes through increased tumor cell destruction. The research includes preclinical models to assess the safety and effectiveness of this innovative treatment strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older diagnosed with glioblastoma.
Not a fit: Patients with other types of brain tumors or those under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new, more effective treatment option for patients with glioblastoma.
How similar studies have performed: This approach is novel and has not been previously explored using herpes simplex virus-based oncolytic therapy, although similar strategies in other contexts have shown promise.
Where this research is happening
DUARTE, UNITED STATES
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE — DUARTE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CALIGIURI, MICHAEL A — BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
- Study coordinator: CALIGIURI, MICHAEL A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.